Prognostic significance of mucin antigen MUC1 in various human epithelial cancers a meta-analysis

Medicine (United States)

Volumn 94, Issue 50, 2015, Pages

  Xu, Feng ^a   Liu, Fuquan ^b   Zhao, Hongwei ^b   An, Guangyu ^a   Feng, Guosheng ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MUCIN 1;

ADVANCED CANCER; ARTICLE; BILE DUCT CARCINOMA; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CARCINOMA; COCHRANE LIBRARY; COLORECTAL CANCER; EMBASE; GENE OVEREXPRESSION; HUMAN; LYMPH NODE METASTASIS; MEDLINE; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; METABOLISM; MORTALITY; NEOPLASMS, GLANDULAR AND EPITHELIAL; PROGNOSIS;

HUMANS; MUCIN-1; NEOPLASMS, GLANDULAR AND EPITHELIAL; PROGNOSIS;

EID: 84952667732     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002286     Document Type: Article

References (48)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: Cancer J Clin. 2015;65:5-29.
2. Paul D, Kumar A, Gajbhiye A, et al. Mass spectrometry-based proteomics in molecular diagnostics: discovery of cancer biomarkers using tissue culture. Biomed Res Int. 2013;2013:783131.
3. Chang JF, Zhao HL, Phillips J, et al. The epithelial mucin, MUC1, is expressed on resting T lymphocytes and can function as a negative regulator of T cell activation. Cell Immunol. 2000;201:83-88.
4. Lau SK, Weiss LM, Chu PG. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am J Clin Pathol. 2004;122:61-69.
5. Wesseling J, van der Valk SW, Vos HL, et al. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol. 1995;129:255-265.
6. Schroeder JA, Masri AA, Adriance MC, et al. MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene. 2004;23:5739-5747.
7. Kimura T, Finn OJ. MUC1 immunotherapy is here to stay. Expert Opin Biol Ther. 2013;13:35-49.
8. Ilhan O, Han U, Onal B, et al. Prognostic significance of MUC1, MUC2 and MUC5AC expressions in gastric carcinoma. Turk J Gastroenterol. 2010;21:345-352.
9. Baldus SE, Monig SP, Huxel S, et al. MUC1 and nuclear betacatenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res. 2004;10:2790-2796.
10. Winter JM, Tang LH, Klimstra DS, et al. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One. 2012;7:e40157.
11. van der Vegt B, de Roos MA, Peterse JL, et al. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. Histopathology. 2007;51:322-335.
12. Sivridis E, Giatromanolaki A, Koukourakis MI, et al. Patterns of episialin/MUC1 expression in endometrial carcinomas and prognostic relevance. Histopathology. 2002;40:92-100.
13. Hirasawa Y, Kohno N, Yokoyama A, et al. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med. 2000;161(2 Pt 1):589-594.
14. Abd Elazeez TA, El-Balshy Ael L, Khalil MM, et al. Prognostic significance of P27 (Kip 1) and MUC1 in papillary transitional cell carcinoma of the urinary bladder. Urol Ann. 2011;3:8-13.
15. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603-605.
16. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
17. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Metaanalysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-2012.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
19. Xie S, Wang K, Xu H, et al. PRISMA-extracapsular dissection versus superficial parotidectomy in treatment of benign parotid tumors: evidence from 3194 patients. Medicine. 2015;94:e1237.
20. McGuckin MA, Walsh MD, Hohn BG, et al. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Human Pathol. 1995;26:432-439.
21. Guddo F, Giatromanolaki A, Koukourakis MI, et al. MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol. 1998;51:667-671.
22. Baldus SE, Zirbes TK, Engel S, et al. Correlation of the immunohistochemical reactivity of mucin peptide cores MUC1 and MUC2 with the histopathological subtype and prognosis of gastric carcinomas. Int J Cancer. 1998;79:133-138.
23. Utsunomiya T, Yonezawa S, Sakamoto H, et al. Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. Clin Cancer Res. 1998;4:2605-2614.
24. Higashi M, Yonezawa S, Ho JJ, et al. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology. 1999;30:1347-1355.
25. Matsumura N, Yamamoto M, Aruga A, et al. Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma. Cancer. 2002;94:1770-1776.
26. Lee HS, Lee HK, Kim HS, et al. MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators. Cancer. 2001;92:1427-1434.
27. Baldus SE, Monig SP, Hanisch FG, et al. Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis (a) and sialyl-Lewis (x) antigens in colorectal adenocarcinoma. Histopathology. 2002;40:440-449.
28. Akyurek N, Akyol G, Dursun A, et al. Expression of MUC1 and MUC2 mucins in gastric carcinomas: their relationship with clinicopathologic parameters and prognosis. Pathol Res Pract. 2002;198:665-674.
29. Wang JY, Chang CT, Hsieh JS, et al. Role of MUC1 and MUC5AC expressions as prognostic indicators in gastric carcinomas. J Surg Oncol. 2003;83:253-260.
30. Nagai S, Takenaka K, Sonobe M, et al. A novel classification of MUC1 expression is correlated with tumor differentiation and postoperative prognosis in non-small cell lung cancer. J Thorac Oncol. 2006;1:46-51.
31. Duncan TJ, Watson NF, Al-Attar AH, et al. The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer. World J Surg Oncol. 2007;5:31.
32. Woenckhaus M, Merk J, Stoehr R, et al. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. Human Pathol. 2008;39:126-136.
33. Togami S, Nomoto M, Higashi M, et al. Expression of mucin antigens (MUC1 and MUC16) as a prognostic factor for mucinous adenocarcinoma of the uterine cervix. J Obstet Gynaecol Res. 2010;36:588-597.
34. Park SY, Roh SJ, Kim YN, et al. Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact. Oncol Rep. 2009;22:649-657.
35. Ando H, Aihara R, Ohno T, et al. Prognostic significance of the expression of MUC1 and collagen type IV in advanced gastric carcinoma. Br J Surg. 2009;96:901-909.
36. Westgaard A, Schjolberg AR, Cvancarova M, et al. Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours. Histopathology. 2009;54:337-347.
37. Retterspitz MF, Monig SP, Schreckenberg S, et al. Expression of {beta}-catenin, MUC1 and c-met in diffuse-type gastric carcinomas: correlations with tumour progression and prognosis. Anticancer Res. 2010;30:4635-4641.
38. Situ D, Wang J, Ma Y, et al. Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer. Medical Oncol (Northwood, London, England). 2011;28(Suppl 1):S596-S604.
39. Kim SM, Oh SJ, Hur B. Expression of MUC1 and MUC4 in gallbladder adenocarcinoma. Korean J Pathol. 2012;46:429-435.
40. Hamada T, Nomura M, Kamikawa Y, et al. DF3 epitope expression on MUC1 mucin is associated with tumor aggressiveness, subsequent lymph node metastasis, and poor prognosis in patients with oral squamous cell carcinoma. Cancer. 2012;118:5251-5264.
41. Khanh do T, Mekata E, Mukaisho K, et al. Transmembrane mucin MUC1 overexpression and its association with CD10 (+) myeloid cells, transforming growth factor-beta1 expression, and tumor budding grade in colorectal cancer. Cancer Sci. 2013;104:958-964.
42. Liu S, Ruan M, Li S, et al. Increased expression of MUC1 predicts poor survival in salivary gland mucoepidermoid carcinoma. J Craniomaxillofac Surg. 2014;42:1891-1896.
43. Lacunza E, Baudis M, Colussi AG, et al. MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet Cytogenet. 2010;201:102-110.
44. Lagow EL, Carson DD. Synergistic stimulation of MUC1 expression in normal breast epithelia and breast cancer cells by interferongamma and tumor necrosis factor-alpha. J Cell Biochem. 2002;86:759-772.
45. Rajabi H, Jin C, Ahmad R, et al. Mucin 1 oncoprotein expression is suppressed by the mir-125b oncomir. Genes Cancer. 2010;1:62-68.
46. Roy LD, Sahraei M, Subramani DB, et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene. 2011;30:1449-1459.
47. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia. 2001;6:339-353.
48. Kovjazin R, Volovitz I, Kundel Y, et al. ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors. Vaccine. 2011;29:4676-4686.